Experimental estimate · v0.11

Paraguay chikungunya outbreak

Paraguay1 Oct 2022 – 11 Mar 2023

Report prepared 8 October 2026

Estimated USU1.3 million

Acute illness and fatal courses

Reported deaths52

Attributable; probable / confirmed subset. Source context

Cases modeled81,037

reported cases

1 USU is the modeled burden of one specified six-hour kidney-stone pain reference. It is a common reporting unit, not a claim that the experiences feel the same.

Approximate, assumption-based USU for the included experience. Deaths are a separate measure. Includes fatal illness.

What this estimate tells us

The estimate is about 1.32 million USU. Most comes from the ordinary acute courses; the separate fatal course changes the previous estimate by about 0.22%. This modest change reflects the small selected fatal group, not the importance of the lives lost.

From one modeled experience to the total

Cases in the reported total
81,037
Modeled average per case
≈ 16.3 USU
Estimated total
≈ 1.3 million USU

Population count × modeled average ≈ total USU

This is a modeled average across the included cases. Other cases in the reported total are assigned about 16.3 USU each; CHIKV-attributable fatal cases are assigned about 71.1 USU each. Each course is weighted by its case count. The average can differ between outbreaks because the reported mix of cases differs, even when the same course assumptions are used. See the two courses and their assumed durations →

This is an assumption-based average, not an observed average or a prediction for any individual. Figures shown here are rounded; calculations use unrounded values. How to read these averages.

The fatal course is provisional and borrowed from another setting. Paraguay’s 52 attributable deaths include eight neonates and 32 adults aged 60 or older. One shared course simplifies these very different experiences; it is not validated for each age group. Persistent joint symptoms outside the assigned courses remain unestimated.

Two groups, one course per case

81,037 suspected, probable or confirmed cases = 80,985 other cases in the reported total + 52 CHIKV-attributable fatal cases. “Other” means cases outside the selected attributable fatal group. It includes unresolved outcomes and cases whose deaths were assigned another cause; it does not mean known survivors or mild cases. We do not infer additional deaths from the subset.

Other cases in the reported total

80,985 cases

8 days × average intensity 4

80,985 × 8 × 24 × 4 ÷ 47.25

≈ 16.3 USU per case

Estimated total for this group: about 1.3 million USU.

CHIKV-attributable fatal cases

52 cases

28 days × average intensity 5

52 × 28 × 24 × 5 ÷ 47.25

≈ 71.1 USU per case

Estimated total for this group: about 3.7 thousand USU.

Combined estimateAbout 1.32 million USU

Rounded for readability. The downloadable inputs retain the calculation precision.

The fatal course replaces the ordinary allowance for those same cases. It covers the complete illness ending at death, so there is no additional terminal-period charge. Death itself, lost life years and bereavement are not assigned USU.

Intensity is a combined 0–10 average over the elapsed course, including relief, sleep and intervals without experience. No intensity is assigned after death or to known absence of experience. Why divide by 47.25?

Why these durations and intensities?

Chikungunya: other reported cases

CDC describes acute symptoms typically resolving within 7-10 days. We retain eight days for cases outside the selected CHIKV-attributable fatal group. This is a representative choice, not an observed outbreak mean or proof of survival; unresolved outcomes and other-cause deaths are not reclassified. Persistent joint symptoms are excluded from this ordinary course. [S4]

CDC describes potentially severe, debilitating joint symptoms; Paraguay's adult suspected-case definition included incapacitating joint pain or arthritis. These support testing a higher average than dengue. Assigned intensity 4, and the 4:3 ratio, remain model judgments rather than measured equivalence. [S3] [S4]

Chikungunya: attributable fatal illness

A Ceará, Brazil series reported a mean onset-to-death interval of 28 days and a median of 15 days across 245 laboratory-confirmed deaths. We borrow the mean for this simple aggregate model. It includes later deaths and is not a measured Paraguay average. Differences in ages, care and death attribution limit transferability. The course represents the complete symptomatic illness ending at death, not an extra terminal period. [S21]

We assign intensity 5 as a combined elapsed-time average, above the ordinary value 4. A Paraguay adult ICU study describes fever, gastrointestinal symptoms and neurological involvement, but does not measure USU intensity or a complete onset-to-death course. The exact value and 5:4 ratio are judgments, allowing for relief, sleep and intervals without experience. This is not a constant conscious pain score. No suffering is assigned after death. [S22]

What changed in version 0.6?

Version 0.5 assigned the same 8-day, intensity-4 course to all 81,037 cases: 1,317,172.83 USU. The revised estimate is 1,320,025.40 USU, a change of +2,852.57 USU (+0.217%).

For the 52 reported fatal cases, 845.21 USU is removed and replaced with 3,697.78 USU. The reference unit and source counts are unchanged.

What changes the estimate?

Under the central assumptions, other cases in the reported total contribute 99.7%; chikv-attributable fatal cases contribute 0.3% of the total. Both courses are varied below.

Each row uses the same reported counts and included experiences. The lower and higher rows change duration and intensity together for every included course.

Illustrative scenarios for the whole estimate
ScenarioAssumed coursesEstimated USU
Lower assumptionsOther cases in the reported total: 7 days at intensity 3
CHIKV-attributable fatal cases: 15 days at intensity 4
865 thousand
Central assumptionsOther cases in the reported total: 8 days at intensity 4
CHIKV-attributable fatal cases: 28 days at intensity 5
1.32 million
Higher assumptionsOther cases in the reported total: 10 days at intensity 5
CHIKV-attributable fatal cases: 42 days at intensity 6
2.06 million

These are alternative assumptions, not confidence intervals or bounds. Counts can be incomplete or misclassified; omitted experiences and the validity of the intensity scale remain outside this calculation. Actual burden could fall outside these examples.

Change one assumption at a time

Only the named input changes. Every other duration, intensity and count stays at its central value. Each result is the total for the whole report.

Effect of individual inputs
Input variedLower input and resulting totalHigher input and resulting total
Other cases in the reported total
Duration
7 days
1.16 million USU
10 days
1.65 million USU
Other cases in the reported total
Average intensity
3 / 10
991 thousand USU
5 / 10
1.65 million USU
CHIKV-attributable fatal cases
Duration
15 days
1.32 million USU
42 days
1.32 million USU
CHIKV-attributable fatal cases
Average intensity
4 / 10
1.32 million USU
6 / 10
1.32 million USU

Fatal illness remains a replacement course for the same reported fatal cases; no case is counted twice. How the scenarios are chosen.

Download scenario calculations (CSV) · Reproduce the scenarios (Python)

What goes into this number?

Included

80,985 other cases receive an eight-day course at intensity 4. The 52 CHIKV-attributable fatal cases receive a complete 28-day course at intensity 5 in place of that allowance. Concurrent symptoms are combined, and each case receives one course.

Source population and period

Torales et al., CDC MMWR, 9 June 2023: 81,037 suspected, probable or confirmed cases during 1 October 2022-11 March 2023. Discarded negative-tested cases are excluded by the source. This is an interim outbreak count, not the final 2023 total. [S3]

Outside this estimate

Persistent or recurrent joint pain beyond the assigned course, extra severity profiles for other cases, caregiver distress, bereavement, unreported infections, death itself, lost life years and suffering after death.

Omitted experiences are unestimated, not known to be zero. This is not a complete event total or a guaranteed lower bound.

Whole representative courses are assigned to the source-defined cases or cohort. Course time can extend beyond the reporting dates. The fatal course ends at death; individual symptom histories and timing are not reconstructed. Other cases include unresolved outcomes, and no future deaths are imputed. No causal baseline or suffering after death is assigned.

Mortality source context

52 CHIKV-attributable deaths among 47,116 probable or confirmed cases within the broader 81,037-case total. The death count remains separate from USU and identifies the cases receiving a complete fatal course. [S3]

Suffering before death: included

A complete fatal illness course is included for 52 source-defined fatal cases. It replaces their ordinary allowance; each case receives one course. This does not cover every possible death or consequence.

See the two-group calculation →

Why this death count fits the calculation: MMWR places 52 CHIKV-attributable deaths within 47,116 probable or confirmed cases, themselves part of the 81,037 suspected, probable or confirmed cases reported through 11 March 2023. We replace the allowance for those 52 only. Deaths attributed to other causes and deaths pending review do not receive this replacement. The report does not provide one complete all-age count for those other categories. No fatality rate is extrapolated to suspected cases. [S3]

USU estimates experienced suffering during lived time. Death itself and lost life years are not assigned USU. A report can use a death count to identify a distinct course of suffering before death, as in the disease fatal-course calculations. Bereavement remains unestimated.

Sources and calculation data

Related reading

The Mauritius 2026 report applies the same acute course to another dated snapshot. Reporting definitions and coverage differ, so the totals do not establish a ranking of complete outbreak burdens.

Explore the USU research background

Search WSI